33324193|t|Frontal and Cerebellar Atrophy Supports FTSD-ALS Clinical Continuum.
33324193|a|BACKGROUND: Frontotemporal Spectrum Disorder (FTSD) and Amyotrophic Lateral Sclerosis (ALS) are neurodegenerative diseases often considered as a continuum from clinical, epidemiologic, and genetic perspectives. We used localized brain volume alterations to evaluate common and specific features of FTSD, FTSD-ALS, and ALS patients to further understand this clinical continuum. METHODS: We used voxel-based morphometry on structural magnetic resonance images to localize volume alterations in group comparisons: patients (20 FTSD, seven FTSD-ALS, and 18 ALS) versus healthy controls (39 CTR), and patient groups between themselves. We used mean whole-brain cortical thickness (  C T    ) to assess whether its correlations with local brain volume could propose mechanistic explanations of the heterogeneous clinical presentations. We also assessed whether volume reduction can explain cognitive impairment, measured with frontal assessment battery, verbal fluency, and semantic fluency. RESULTS: Common (mainly frontal) and specific areas with reduced volume were detected between FTSD, FTSD-ALS, and ALS patients, confirming suggestions of a clinical continuum, while at the same time defining morphological specificities for each clinical group (e.g., a difference of cerebral and cerebellar involvement between FTSD and ALS).  C T    values suggested extensive network disruption in the pathological process, with indications of a correlation between cerebral and cerebellar volumes and  C T    in ALS. The analysis of the neuropsychological scores indeed pointed toward an important role for the cerebellum, along with fronto-temporal areas, in explaining impairment of executive, and linguistic functions. CONCLUSION: We identified common elements that explain the FTSD-ALS clinical continuum, while also identifying specificities of each group, partially explained by different cerebral and cerebellar involvement.
33324193	0	30	Frontal and Cerebellar Atrophy	Disease	MESH:D002526
33324193	40	44	FTSD	Disease	MESH:D057180
33324193	45	48	ALS	Disease	MESH:D000690
33324193	81	113	Frontotemporal Spectrum Disorder	Disease	MESH:D057180
33324193	115	119	FTSD	Disease	MESH:D057180
33324193	125	154	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
33324193	156	159	ALS	Disease	MESH:D000690
33324193	165	191	neurodegenerative diseases	Disease	MESH:D019636
33324193	367	371	FTSD	Disease	MESH:D057180
33324193	373	378	FTSD-	Disease	MESH:D057180
33324193	378	381	ALS	Disease	MESH:D000690
33324193	387	390	ALS	Disease	MESH:D000690
33324193	391	399	patients	Species	9606
33324193	581	589	patients	Species	9606
33324193	594	598	FTSD	Disease	MESH:D057180
33324193	606	610	FTSD	Disease	MESH:D057180
33324193	611	614	ALS	Disease	MESH:D000690
33324193	623	626	ALS	Disease	MESH:D000690
33324193	666	673	patient	Species	9606
33324193	925	941	volume reduction	Disease	MESH:D015431
33324193	954	974	cognitive impairment	Disease	MESH:D003072
33324193	1150	1154	FTSD	Disease	MESH:D057180
33324193	1156	1160	FTSD	Disease	MESH:D057180
33324193	1161	1164	ALS	Disease	MESH:D000690
33324193	1170	1173	ALS	Disease	MESH:D000690
33324193	1174	1182	patients	Species	9606
33324193	1352	1362	cerebellar	Disease	MESH:D002526
33324193	1383	1387	FTSD	Disease	MESH:D057180
33324193	1392	1395	ALS	Disease	MESH:D000690
33324193	1536	1546	cerebellar	Disease	MESH:D002526
33324193	1570	1573	ALS	Disease	MESH:D000690
33324193	1729	1778	impairment of executive, and linguistic functions	Disease	MESH:D003072
33324193	1839	1843	FTSD	Disease	MESH:D057180
33324193	1844	1847	ALS	Disease	MESH:D000690
33324193	1966	1976	cerebellar	Disease	MESH:D002526

